PMID- 36394696
OWN - NLM
STAT- MEDLINE
DCOM- 20230315
LR  - 20230402
IS  - 1559-0097 (Electronic)
IS  - 1046-3976 (Linking)
VI  - 34
IP  - 1
DP  - 2023 Mar
TI  - Primary Thyroid Mucoepidermoid Carcinoma (MEC) Is Clinically, Prognostically, and 
      Molecularly Different from Sclerosing MEC with Eosinophilia: A Multicenter and 
      Integrated Study.
PG  - 100-111
LID - 10.1007/s12022-022-09741-1 [doi]
AB  - Mucoepidermoid carcinoma (MEC) and sclerosing MEC with eosinophilia (SMECE) are 
      rare primary thyroid carcinomas. In this study, we aimed to present our 
      multicenter series of MEC and SMECE and integrated our data with published 
      literature to further investigate the clinicopathological characteristics and 
      prognoses of these tumors. We found 2 MECs and 4 SMECEs in our multicenter 
      archives. We performed fluorescence in situ hybridization (FISH) to determine the 
      MAML2 gene rearrangement. We screened for mutations in BRAF, TERT promoter, and 
      RAS mutations using Sanger sequencing and digital polymerase chain reaction. 
      Histopathologically, MECs and SMECEs were composed of two main cell types 
      including epidermoid and mucin-secreting cells, arranged in cords, nests, and 
      tubules. SMECEs were characterized by a densely sclerotic stroma with abundant 
      eosinophils. We did not detect any MAML2 fusion in any of our cases. Two MEC 
      cases harbored concomitant BRAF p.V600E and TERT C228T mutations. RAS mutations 
      were absent in all cases. Concurrent foci of another thyroid malignancy were more 
      commonly seen in MECs (p < 0.001), whereas SMECEs were associated with chronic 
      lymphocytic thyroiditis (p < 0.001). MECs and SMECEs had equivalent 
      recurrence-free survival (RFS) but MECs conferred significantly dismal 
      disease-specific survival (DSS) as compared to SMECEs (p = 0.007). In conclusion, 
      MECs and SMECEs not only shared some similarities but also demonstrated 
      differences in clinicopathological characteristics, prognoses, and molecular 
      profiles. SMECEs had a superior DSS in comparison to MECs, suggesting that they 
      are low-grade cancers. This could help clinicians better evaluate patient 
      outcomes and decide appropriate treatment plans.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Le, Hieu Trong
AU  - Le HT
AD  - Department of Pathology, University of Medicine and Pharmacy at Ho Chi Minh City, 
      Ho Chi Minh City, 700-000, Vietnam.
FAU - Nguyen, Truong P X
AU  - Nguyen TPX
AD  - Department of Pathology, Chulalongkorn University, Krung Thep Maha Nakhon , 
      Bangkok, 10300, Thailand.
FAU - Hirokawa, Mitsuyoshi
AU  - Hirokawa M
AD  - Department of Diagnostic Pathology and Cytology, Kuma Hospital, Kobe, Hyogo, 
      650-0011, Japan.
FAU - Katoh, Ryohei
AU  - Katoh R
AD  - Department of Pathology, Ito Hospital, Shibuya, Tokyo, 150-8308, Japan.
FAU - Mitsutake, Norisato
AU  - Mitsutake N
AD  - Department of Radiation Medical Sciences, Atomic Bomb Disease Institute, Nagasaki 
      University, Nagasaki, 852-8523, Japan.
FAU - Matsuse, Michiko
AU  - Matsuse M
AD  - Department of Radiation Medical Sciences, Atomic Bomb Disease Institute, Nagasaki 
      University, Nagasaki, 852-8523, Japan.
FAU - Sako, Ayaka
AU  - Sako A
AD  - Department of Radiation Medical Sciences, Atomic Bomb Disease Institute, Nagasaki 
      University, Nagasaki, 852-8523, Japan.
FAU - Kondo, Tetsuo
AU  - Kondo T
AD  - Department of Pathology, University of Yamanashi, Yamanashi, 409-3821, Japan.
FAU - Vasan, Nilesh
AU  - Vasan N
AD  - Department of Otolaryngology, Oklahoma University Health Sciences Center, 
      Oklahoma City, OK, 73104, USA.
FAU - Kim, Young Mi
AU  - Kim YM
AD  - Genetics Laboratory, Oklahoma University Health Sciences Center, Oklahoma City, 
      OK, 73104, USA.
FAU - Liu, Ying
AU  - Liu Y
AD  - Genetics Laboratory, Oklahoma University Health Sciences Center, Oklahoma City, 
      OK, 73104, USA.
FAU - Hassell, Lewis
AU  - Hassell L
AD  - Department of Pathology, Oklahoma University Health Sciences Center, Oklahoma 
      City, OK, 73104, USA.
FAU - Kakudo, Kennichi
AU  - Kakudo K
AD  - Department of Pathology, Cancer Genome Center and Thyroid Disease Center, Izumi 
      City General Hospital, Izumi, Japan.
FAU - Vuong, Huy Gia
AU  - Vuong HG
AD  - Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, 
      52242, USA. huy-vuong@uiowa.edu.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20221117
PL  - United States
TA  - Endocr Pathol
JT  - Endocrine pathology
JID - 9009288
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
RN  - 0 (Transcription Factors)
SB  - IM
CIN - Endocr Pathol. 2023 Mar;34(1):98-99. PMID: 36757639
MH  - Humans
MH  - Thyroid Gland/pathology
MH  - *Carcinoma, Mucoepidermoid/genetics/pathology
MH  - In Situ Hybridization, Fluorescence
MH  - Proto-Oncogene Proteins B-raf/genetics
MH  - Transcription Factors/genetics
MH  - *Eosinophilia/genetics/pathology
OTO - NOTNLM
OT  - BRAF
OT  - Eosinophilia
OT  - MAML2
OT  - MEC
OT  - Mucoepidermoid carcinoma
OT  - SMECE
OT  - TERT
OT  - Thyroid
EDAT- 2022/11/18 06:00
MHDA- 2023/03/16 06:00
CRDT- 2022/11/17 13:56
PHST- 2022/11/05 00:00 [accepted]
PHST- 2022/11/18 06:00 [pubmed]
PHST- 2023/03/16 06:00 [medline]
PHST- 2022/11/17 13:56 [entrez]
AID - 10.1007/s12022-022-09741-1 [pii]
AID - 10.1007/s12022-022-09741-1 [doi]
PST - ppublish
SO  - Endocr Pathol. 2023 Mar;34(1):100-111. doi: 10.1007/s12022-022-09741-1. Epub 2022 
      Nov 17.